Global Health Ltd (MEDANTA) Q1 FY27 Results Analysis: Revenue Surges 26.5%, EBITDA Margin Misses Guidance
Global Health Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 1,304.05 Cr (+26.50% YoY) and PAT growth of -1.10% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 30, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 1,304.05 Cr (+26.50% YoY) |
| PAT (Q1) | Rs. 157.25 Cr (-1.10% YoY) |
| EBITDA margin | 22.48% (-220 bps YoY) |
| EPS (Q1) | Rs. 5.91 (-0.20% YoY) |
| Market cap | Rs. 38,083.00 Cr |
| CMP | Rs. 1,416.40 |
Quarter Snapshot
Medanta delivered strong revenue growth of 26.5% YoY, the highest in recent history, driven by capacity additions and volume growth. However, EBITDA margin missed the company's own 24-26% guidance, coming in at 22.48%, as costs from expansion (finance costs, D&A, retainers) outpaced revenue. The quarter saw flat PAT, but subsidiary hospitals are maturing with a 3x jump in contribution, and new catalysts (Guwahati expansion, Indore oncology unit, medical college) position the company for medium-term improvement.
Key Investment Insights
Key Positives
- Revenue grew 26.5% YoY to Rs.1,304.05 Cr, the strongest quarterly print in recent history.
- Subsidiary PAT contribution (new hospitals) jumped 3x to Rs.21.42 Cr, confirming maturing of new capacity.
- EBITDA margin expanded 58 bps QoQ to 22.48%, consistent with narrowing losses at Noida.
- Cost of materials as % of revenue declined 95 bps YoY.
Risk Factors
- EBITDA margin of 22.48% missed the company's own FY27 guidance of 24-26% by ~152 bps.
- Reported PAT was flat YoY (-0.2%) and normalized PAT declined 9.6% YoY, despite 26.5% revenue growth.
- Finance costs doubled YoY (+93.5%) and D&A rose 52.9% YoY, reflecting the capital-intensive expansion.
- Retainers & consultants fee as % of revenue rose 213 bps YoY to 15.39% due to clinical talent onboarding.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.